In chronic myalogenous leukemia (CML), leukemic blood cells can be distinguished from other cells of the body by the presence of a functional BCR-ABL hybrid protein. Explain how this characteristic provides an opportunity to develop a therapeutic approach to a treatment for CML
¦ HINT: This problem asks you to imagine a therapy that is based on the unique genetic characteristic of CML leukemic cells. The key to its solution is to remember that the SCI•BL fusion protein is found only in CML white blood cells and that this unusual protein has a specific function thought to directly contribute to the development of CML. To help you answer this problem, you may wish to learn more about the cancer drug Gleevec (see http:// www.nci.nih.govinewscenter/qandagleevec).
We need at least 10 more requests to produce the solution.
0 / 10 have requested this problem solution
The more requests, the faster the answer.